**Name of Journal: *World Journal of Gastrointestinal Oncology***

**Manuscript NO: 46768**

**Manuscript Type: REVIEW**

**Premalignant lesions and gastric cancer: Current understanding**

Koulis A *et al*. Premalignant lesions and gastric cancer

**Athanasios Koulis, Andrew Buckle, Alex Boussioutas**

**Athanasios Koulis, Andrew Buckle, Alex Boussioutas,** Upper Gastrointestinal Translational Laboratory, Peter MacCallum Cancer Centre, Melbourne 8006, Australia

**Athanasios Koulis, Andrew Buckle, Alex Boussioutas,** Sir Peter MacCallum Department of Surgical Oncology, University of Melbourne, Melbourne 8006, Australia

**ORCID number:** Athanasios Koulis (0000-0003-8939-8839); Andrew Buckle (0000-0002-2180-0555); Alex Boussioutas (0000-0002-8109-6897).

**Author contributions:** All authors equally contributed to this paper with conception, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** The authors declare having no potential conflicts of interest related to this paper.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Alex Boussioutas, MBBS, PhD, FRACP,** Upper Gastrointestinal Translational Laboratory, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Victoria 8006, Australia. alex.boussioutas@petermac.org

**Telephone:** +61-3-85595000

**Received:** February 25, 2019

**Peer-review started:** February 26, 2019

**First decision:** May 24, 2019

**Revised:** May 29, 2019

**Accepted:** August 20, 2019

**Article in press:**

**Published online:**

# **Abstract**

Over the last two decades, there has been a broad paradigm shift in our understanding of gastric cancer and its premalignant states, from gross histological models to increasingly precise molecular descriptions. In this review, we reflect upon historic approaches for describing premalignant lesions and gastric cancer, and highlight the current molecular landscape and how this may inform future risk assessment prevention strategies.

**Key words:** *Helicobacter pylori*; Correa cascade; Atrophic gastritis; Intestinal metaplasia; Point of no return; Dysplasia; Stem cells; Gastric cancer

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Despite recent advances in our understanding of the molecular and cellular events involved in gastric cancer, little is known about how gastric premalignant lesions actually lead to this usually lethal disease (5-year survival of about 20% in most Western countries). It is still not clear whether some or all of these lesions are directly involved in the process of gastric carcinogenesis or whether they are simply bystanders. In this review, we attempt to shed some light on how our current understanding of premalignant lesions may be used to improve patient stratification and lead to better overall patient survival rates.

Koulis A, Buckle A, Boussioutas A. Premalignant lesions and gastric cancer: Current understanding. *World J Gastrointest Oncol* 2019; In press

## **Introduction**

Gastric cancer (GC) is the fifth most common cancer worldwide and third highest cause of cancer-related death. In 2012, 950,000 individuals were diagnosed with the disease and 723,000 died. High incidence areas are Eastern Asia, particularly China, Japan and South Korea, Eastern Europe, Central and South America. Low incidence areas are Australia and New Zealand, North America, Western Europe, South Central Asia, and most parts of Africa[1]. Risk factors for GC include the following: male sex; age; high salt intake, including of salt-preserved foods, smoked or dried meat and fish, pickled food; low intake of fresh fruit and vegetables; smoking; radiation exposure; low levels of physical activity; obesity; and low socioeconomic status[2-15].

## **Histological and Molecular Classifications of GC**

The majority of GCs are adenocarcinomas that can be subdivided by the Lauren histopathology system into intestinal (IG)C and diffuse (D)GC subtypes[16]. IGC is characterised by tumour cells that form gland-like structures, whereas DGC has single or groups of tumour cells that are poorly differentiated or undifferentiated infiltrating the gastric wall. GC with components of both DGC and IGC are referred to as mixed. Given that all three subtypes are adenocarcinomas, this raises questions regarding the pre-malignant pathways and aetiologies of each. Given that they arise from the same gastric inflammatory milieu, are they a spectrum of the same disease with overlapping molecular identities or do they represent unique entities with disparate causes and premalignant pathways?

The Cancer Genome Atlas (TCGA) Research Network published a landmark study into molecular classification of established GC in 2014. The study performed integrative genomic and epigenomic analyses of 295 gastric adenocarcinomas (GAs) and reported on the following four major subclasses based on somatic copy number, mutation analysis, methylation, and gene expression status: epstein barr virus-positive, microsatellite instability (MSI), genomically stable, and chromosomal unstable subtypes[17]. While there is significant overlap regarding the molecular signatures among the IGC, DGC, and mixed types consistent with common aspects of oncogenesis, 75% of DGCs are of the genomically stable subclass, suggesting a divergent pathway. TCGA analysis also demonstrates the potential limitation of histological systems such as the Lauren classification, with cellular phenotypes often not reflecting the heterogeneous nature of complex underlying molecular changes.

There are a number of inherited genetic conditions that predispose to GC such as somatic mismatch repair mutations in Lynch Syndrome and cadherin-1 (CDH1) mutations in hereditary diffuse GC. Although these are of interest in elucidating the molecular pathways of oncogenesis, discussion of these conditions is largely outside the scope of this review.

## **The Correa Cascades**

## ***Chronic gastric inflammation***

In 1975, Correa *et al*[18] described a stepwise progression of conditions within the stomach that are thought to result in GC. This was one of the first considerations of premalignant conditions in this disease, and it was later found to be initiated by *Helicobacter pylori*. The initial step in the Correa cascade is the development of chronic gastritis (ChG). *H. pylori* represents the archetypal cause of ChG, with infected patients in some studies having a greater than 10-fold higher chance of developing GC[19]. The effects of *H. pylori* on the gastric epithelium have been extensively studied, with one of the most important pathogenic factors being cytotoxin-associated gene A protein (CagA)-positive strains. Virtually all East Asian strains and 60% of Western strains of *H. pylori* strains are CagA+, with infected patients developing more distinct inflammation, gastric ulceration and higher risk of GC[20-22]. Bacterial CagA protein interacts with a series of host epithelial proteins including apoptosis-stimulating of p53 protein 2, runt-related transcription factor 3, phosphoinositide 3-kinase, Src homology 2-containing protein tyrosine phosphatase 2, and E-cadherin, resulting in the degradation and inactivation of p53 and runt-related transcription factor 3; deregulation of the phosphoinositide 3-kinase-AKT, Ras-extracellular signal-related kinase, and Wnt pathways; and disruption of adherens junctions[23]. CagA has also been shown to alter DNA methylation patterns, further deregulating normal epithelial gene expression patterns[24]. Intestinal metaplasia (IM) samples show higher levels of methylation than atrophic gastritis (AG) samples, suggesting that DNA methylation pattern changes may play a vital role in the Correa model of IGC[24,25].

***Autoimmune gastritis and AG***

Autoimmune gastritis is a common aetiology of ChG, which results in activation of the adaptive immune system against parietal cells and intrinsic factor, leading to the destruction of the oxyntic gastric mucosa. As with other forms of chronic inflammation, autoimmune gastritis is a risk factor for GC through progression to IM[26]. In a meta-analysis, the overall relative risk of GC in patients with autoimmune gastritis was 6.8 (95% confidence interval: 2.6-18.1)[27].

ChG leads to AG, which refers to the atrophy and loss of gastric mucosal glands. Loss of specialised cells has significant implications on gastric function, with hypochlorhyria being one of the most recognised. In this state, the loss of peptic acid production and raised gastric pH has implications on nutrient absorption (such as iron) and has significant implications on the gastric microbiome[28]. There has been considerable interest in the relationship between the gastric microbiome and GC, with a recent study uncovering dysbiosis of bacterial taxa along the Correa cascade[29]. At this stage, it is uncertain if this dysbiosis represents a pre-malignant contributing to carcinogenesis in its own right, or simply a reflection of the change in the gastric microenvironment.

A key risk factor of chronic inflammation is the release of large amounts of reactive oxygen species and nitrogen-free species, which are associated with DNA damage and increased mutation rates. Previous studies have shown that reactive oxygen species and nitric oxide synthase (NOS) released by inflammatory and epithelial cells can cause oxidative and nitrative DNA damage including the production of 8-oxo-7,8-dihydro-2’-deoxyguanosine, a known mutagen, and 8-nitroguanine[30,31]. The latter is formed by inducible (iNOS). Gene expression of iNOS is regulated by the nuclear factor-kappa B (NF-B) and signal transducer and activator of transcription pathways among others[32]. These changes can result in DNA mutations, thus promoting cellular changes and carcinogenesis.

### **Gastric stem cells and IM**

In the normal gastric epithelium, stem cell populations give rise to nascent epithelial cells that mature and differentiate as they migrate to the apex of the gland[33]. Gastric and intestinal stem cells share an endodermal lineage, and through the process of chronic inflammation, gastric stem cells may reprogram, producing metaplastic intestinal-type epithelium that replaces the normal gastric mucosa[34]. The continuing chronic inflammatory process results in further accumulation of genetic lesions in stem cells, ultimately resulting in dysplasia and cancer. As such, IM can be thought of as a marker of stem cell stress and damage, with multiple inflammatory aetiologies converging to histologically identical metaplastic change. There have been multiple gastric stem cell populations characterised including leucine rich repeat containing G protein-coupled receptor 5-positive stem cells in the adult antrum and the neonatal corpus and antrum, muscle, intestine and stomach expression 1-positive stem cells found in the isthmus region of the corpus glands, and tumour necrosis factor receptor superfamily, member 19-positive stem cells that are thought to reside in the base of the corpus glands[33,35,36]. The role each of these plays in oncogenesis is an area of ongoing research. However, it is notable that different regions of the stomach have different stems cells and based on epidemiological evidence histological and molecular subgroups are found in different anatomic distributions, suggesting a possible predetermined pathway for conversion to specific GC subgroups. For instance, TCGA found different anatomic distribution of molecular subgroups of GC with MSI being more likely to occur in the gastric corpus and antrum but rarely in the cardia[17].

***IM***

IM is usually found incidentally inpatientsundergoing upper endoscopy and is usually is asymptomatic. While IM is defined by intestinal differentiation, it is molecularly heterogeneous but can be histologically categorised as complete or incomplete subtypes (Figure 1). Complete IM (type I) resembles the small intestine epithelium with goblet cells, Paneth cells, eosinophilic enterocytes, and a brush border[37]. It is associated with loss of markers of gastric mucin (mucin 1 [MUC1], MUC5AC, MUC6) and expression of the intestinal sialic mucin, MUC2[38]. Incomplete IM more closely resembles the large intestine epithelium, lacking absorptive cells, but with columnar cells resembling gastric foveolar cells. It does not have a brush border and maintains expression of gastric mucin markers (MUC1, MUC5AC, MUC6) usually together with gain of MUC2[38]. Incomplete IM is further subdivided into Type II IM, with cells expressing a mixture of neutral mucins and intestinal sialomucins and Type III IM, with cells expressing sulfomucins[37]. In practice, histopathological classification between complete and incomplete IM is often not mutually exclusive, with segments of tissue containing elements of both subtypes. The distinction between complete and incomplete IM is clinically important, as it appears that incomplete harbours a higher risk of progression to cancer[39-42].

In the context of long-term *H. pylori* infection, IM possibly develops as an adaptive and protective lesion[43]. There has been extensive work into determining how *H. pylori* infection leads to IM with a number of genes implicated including sex determining region Y-box 2 (SOX2) and caudal type homeobox 2 (CDX2). SOX2 is a transcription factor involved in gastric differentiation that negatively regulates intestinal differentiation, whereas CDX2 is a key intestinal transcription factor involved in establishing and maintaining IM[44]. SOX2 and CDX2 seem to be inversely regulated by *H. pylori*[45]. Complete IM has been shown to be predominantly SOX2-negative (93%) and incomplete IM mainly SOX2-positive (85%)[46]. Moreover, CDX2 expression has also been shown to be induced in part through an NF-B-dependent mechanism following *H. pylori* infection[47].

Duodeno-gastric reflux is another proposed gastric insult contributing to ChG and IM formation, analogous to gastroesophageal acid reflux in Barrett’s oesophagus[48]. An association of increased incidence of IM after exposure to bile acids was reported in a large-scale study involving 2283 patients[49]. In this context, the development of IM may represent a protective mechanism, with a metaplasia to intestinal phenotype more capable of resisting the effects of bile than the normal gastric mucosa.

## ***Risk factors in IM***

*H. pylori* is a significant risk factor in the establishment of IM; however, there are other clinical and environmental exposures that are important risk factors for IM progression to GC. In a large-scale United States study (*n* = 810821 patients), IM was more common in men, and more prevalent with increasing age and East Asian ancestry. This suggests that IM may occur due to environmental exposures but in the context of hereditary risk[50]**.** Hereditary risk is relevant in GC even excluding major genetic syndromes, with several studies showing that intestinal-type GC is associated with a strong family history of GC[51-53]. With respect to premalignant lesions, it has been shown that among siblings with a family history of any precancerous change, there is an increase in risk of subsequent non-cardia GC with a hazard ratio of 2.5 compared with siblings of index persons with “normal or minor mucosal changes”[54]. The availability of siblings' precancerous data to the clinician could be useful in assessing a patient’s risk of progressing to GC.

Once established, the degree of IM is related to the risk of progression to cancer. Extensive IM with IM in the corpus, and incomplete IM and IM located along the Maggenstrasse (along the lesser curve of the stomach) have been shown to increase the risk of progression towards cancer[40,42,55,56]. In one study of MSI, this molecular finding was enriched in GC and adjacent IM, suggesting this may be an early event in MSI subtype GCs. It is notable that MSI IM was of incomplete type in this study[57], which provides further evidence of the potential unique molecular pathways that begin in the premalignant context.

## **OLGA and OLGIM**

Both the Operative Link on Gastritis Assessment (OLGA) and on Operative Link on Gastric Intestinal Metaplasia (OLGIM) are based on histological assessment of random biopsies taken from designated areas of the stomach according to the Sydney protocol[58-60]. At least four sites are sampled from the stomach during upper gastroscopy (two antral and two corpus). Both OLGA and OLGIM are scoring standards used to grade and stage chronic gastric (CG) inflammation, gastric atrophy, and IM. They provide information with regards to topography and extent of AG and IM, the latter being easier to assess and more consistent. Initially reported by Rugge *et al*[61,62] 2010 and 2011 for both OLGA and OLGIM and more recently by the meta-analysis carried out by Yue *et al*[63] 2018. OLGA and OLGIM stages Type III/IV are consistently associated with increased risk of progression to GC. These findings suggest that high-risk patients with OLGA/OLGIM stages type III/IV would benefit from close and frequent monitoring to detect neoplastic lesions at the earliest possible stage.

## **Point of no return**

The Correa cascade is often referred to as a linear progression; however, in the majority of patients there may be little to no change along the Cascade over many years. In other patients, it can be a dynamic process with regression and/or progression of lesions, perhaps even rapid progression bypassing some of the putative stages. It is clearly evident that *H. pylori* infection and chronic inflammation in selected individuals causes progression of the cascade, and it has been observed that successful eradication of *H. pylori* can lead to regression of histological features. There has been speculation that there is a point at which eradication is less effective at causing regression and indeed does not change the risk of progression in certain individuals. This has been referred as the “point of no return.” *H. pylori* eradication results in complete resolution of histological inflammation and regression of atrophy in AG patients, with greater improvement seen in corpus AG compared to antral AG patients[64]. Unfortunately, the same effect is not seen in IM patients[64-67]. Once IM is established, eradication is only partially successful at reducing the risk of progression to GC. This suggests that IM may be the “point of no return” where genetic damage to gastric stem cells becomes irreversible. Although there is much evidence to support a point of no return, there has been evidence of regression from IM to AG or ChG in some cohorts[40,68]. A graphical summary of some of the larger IM progression studiesis shown in Figure 2[40,68-73].

## **Spasmolytic Peptide Expressing Metaplasia**

Work from animal models of GC has introduced the concept of spasmolytic polypeptide-expressing metaplasia (SPEM). This is a cell lineage shown to be strongly associated with CG in the fundus and GA in animals[74]. It is often thought of as an alternative metaplastic lineage to IM. SPEM is morphologically similar to Brunner's glands of the duodenum and expresses the trefoil factor 2 or spasmolytic polypeptide[75]. It has been hypothesised that SPEM is an alternative precursor to GC and is associated with increased risk compared to IM[76]. Although SPEM is not a defined stage in the Correa cascade, it has been useful for studying the process of metaplasia formation in mice. To avoid confusion, SPEM is identified in the corpus and the fundus but not in the antrum as its characteristics are very similar to those of the deep antral and pyloric glands, which also express TFF2. In mice infected with *H. felis*, SPEM develops after 6 to 12 mo of infection in the presence of active inflammation. First parietal cells are lost (oxyntic atrophy), and then the normal gastric lineages are replaced with metaplastic cells[77]. In two acute drug-induced SPEM models, with DMP-777 protonophore (abrogated inflammation) and L635 (prominent inflammation) as well as with *H. felis* infection in mice (chronic inflammation), it is suggested SPEM arises from the transdifferentiation of chief cells[77,78].However more recently a study by Kinoshita *et al*[79] suggested that SPEM is the result of a regenerative process initiated by neck progenitor cells after chief cell loss. In another mouse model, SPEM in INS-GAS mice progressed to dysplasia after 1 year[80]. Following *H. pylori* infection, Mongolian gerbils progressively develop CG, followed by loss of parietal cells and metaplasia[81]. After 1 year of infection, SPEM is observed and mixed glands expressing both SPEM and IM are also seen. In humans, there is growing evidence suggesting that SPEM can either progress directly to dysplasia or become IM in the presence of continuous chronic inflammation[82]. These animal systems have been useful for studying the natural history of these lesions, but it remains to be seen whether they are reliable models of the human condition.

## **role of the immune microenvironment**

We have continually reiterated the role of chronic inflammation in the development of GC. In the context of a chronically inflamed microenvironment, there is some evidence that IM may arise due to the actions of specific immune cells. Using the murine model of L635-induced SPEM and following administration of clodronate, it was shown that macrophages are involved in the development of acute SPEM[83]. These macrophages were predominantly of the M2 subset (alternatively activated) and in the same study, M2 macrophages were also shown to be increased in human SPEM and IM. Another prevalent immune cell in IM is neutrophils, which have been shown to be approximately 9-fold enriched compared to normal gastric tissue[84]. GC tissues were roughly 24-fold enriched in neutrophils compared to normal gastric tissue. Thus, macrophages and neutrophils may be vital immune cells required in the gastric microenvironment for SPEM and IM to develop and then progress to GC. However, the role of the immune system in the process of GC has not been fully investigated.

## **Cellular and molecular pathways of progression**

IM progression to dysplasia and subsequent cancer occurs infrequently, and the molecular mechanisms responsible for this progression are still not well understood. There are a number of challenges with studying this paradigm in view of the long duration over which these conditions progress, thus limiting prospective studies. This is compounded by the low rates of progression from each of the Correa stages and the potential confounder of tissue sampling when undertaking endoscopic follow-up. Although the exact genomic or epigenomic pathways for IM progression to dysplasia are still being investigated, it is possible to postulate how certain events are necessary for progression by combining available data from a small number of key studies. It is known that: (1) IM is clonally derived from within the gastric mucosa[34,85]; (2) Gastric and IM glands divide by fission to form clonal patches[34,85,86]; (3) Over time, different gastric stem cells with accumulated genomic events (somatic mutations/chromosomal copy number gains and/or losses) can give rise to unique IM glands; (4) Further genomic changes may drive IM glands to proliferate or persist over a long period of time; (5) Dysplastic glands are formed that are genetically related to IM glands, and entire dysplastic fields can share a foundation mutation[86] from which multiple subclones can result; and (6) This event can happen simultaneously in multiple regions of the stomach leading to an increased risk of GC developing across several locations and therefore providing a field cancerisation effect.

To better understand how this process may unfold, studies on GA and Barrett’s oesophagus (BO) progression to GC and oesophageal adenocarcinoma (OAC), respectively, can be used as examples. In a recent study, GA and paired GC from the same patients were used to determine clonal evolution. Clonal structure analyses showed that most GA/GC pairs exhibit parallel evolution with early divergence instead of a linear sequence of GA to GC progression[87]. Additionally, a small number of GC cases were clonally unrelated from paired GA, suggesting the synchronous evolution of multiple clones that may progress to GC. BO is a premalignant intestinal metaplastic lesion that is often associated with gastro-oesophageal disease and predisposes patients to develop OAC[88]. Although exact values differ among studies, two population-based BO follow-up studies showed that the annual risk of progression of BO is 0.12%-0.14%[89,90]. BO has a higher mutation load (6.76 single nucleotide variants [SNVs]/Mb) than gastric IM but still lower than OAC (10.02 SNVs/Mb) and has been shown to be polyclonal[91]. In one patient with BO, high-grade dysplasia (HGD) was shown to arise from multiple clones suggesting that the severity of IM (a result of clonal expansion and cumulative molecular aberrations) may also play a key role in synchronous progression to GC[91].

Overall, a holistic molecular approach is needed to elucidate the crucial events of how premalignant lesions actually cross the bridge to malignancy, a so-called “Pre-Cancer Genome Atlas”[92]. Using whole genome methyl-binding domain sequencing and reduced-representation bisulfite sequencing analyses, Kim et *al*[93] showed that hypermethylation of gastrointestinal hormone receptors may play a key role in early GC. Both gastrin and gastric acid secretion are thought to play important roles in cell differentiation and may play a part in creating a permissive environment or are even directly involved in the process of GC. A good summary review on the potential cellular and molecular pathways of GC was written by Rivas-Ortiz, which added useful insights to this area[94]. It is very likely that GC is the result of multiple events co-occurring over time and space leading to various subtypes of GC (see TCGA molecular subtypes). If this is true, then it is also likely that differing sets of pre-cancerous events contribute to GC. Although some events may overlap across all GC subtypes (*e.g.*, CG), others may be specific for a particular GC subtype (*e.g.*, breakdown of cellular mechanisms that keep diploidy intact leading to the chromosomal instability subtype).

## **High-Risk Genomic and Epigenomic Alterations in IM**

The median time for gastric IM to progress to GC is estimated to be 6.1 years, in contrast to low-grade dysplasia (LGD), which is only 2.6 years[95]. A recent study of genomic and epigenomic profiling of IM showed that IM has a low mutational burden compared to non-hypermutated GC (2.6 *vs* 6.9 mutations/Mb) and harbours recurrent mutations in certain tumour-suppressor genes like F-Box And WD Repeat Domain Containing 7 (6/108 IM cases) but less in others, specifically tumour protein 53 (TP53) and AT-rich interaction domain 1A (2/108 and 3/108 IM cases)[96]. However, the presence of low-frequency TP53 mutations in IM patients is in contrast to previous work within our group, which showed an absence of TP53 mutations in IM samples paired with GC samples from the same patients[97]. A second finding of our study was that overexpression of p53 protein using immunohistochemistry has limited correlation to TP53 mutations. In the Huang *et al*[96] 2018 study, patients that progressed to dysplasia and GC had previous chromosome 8q amplifications and shortened telomeres. Interestingly, patients with IM that regressed had normal epigenomic patterns. DNA methylation profiling showed that the majority of IM patients in the high methylation group had relatively high mutational load, frequent chromosomal copy number variations and F-Box And WD Repeat Domain Containing 7 mutations and occurred mainly in the antrum.

## **LGD and HGD Differ in Mutational Patterns**

The Padova classification was developed in 2000 to standardise histopathological reporting, which identifies five main categories for dysplastic lesions: (1) negative for dysplasia; (2) indefinite for dysplasia; (3) non-invasive neoplasia; (4) suspicious for invasive carcinoma; and (5) invasive adenocarcinoma[98]. In practice, pathologists use categories 1 and 2 and subdivide category 3 as LGD and HGD, the latter being associated with a higher risk of progression. A recent study using targeted deep DNA sequencing of 67 GC-related genes detected adenomatous polyposis coli (APC) mutations in all LGD and also in some HGD cases[99]. However, APC and TP53 appeared to be mutually exclusive, the latter being present only in HGD and diminutive intramucosal GC (diameter < 10 mm). Analysis of tumour variant allele frequency has suggested that TP53 mutation is the initial event in TP53-mutated intramucosal GC. Importantly, this study suggested that linear evolution of LGD to HGD is rare and that early mutational events determine the evolution of dysplastic lesions. Early APC mutations lead to LGD whereas TP53 mutations lead to HGD which, following other genomic aberrations, subsequently evolve into early GC.

## **The Correa Cascade and Diffuse GC**

Although there is considerable evidence of IM progressing to dysplasia and then to IGC, it is still debated whether any of the premalignant lesions that are part of the Correa cascade actually play a role in diffuse GC. In a prospective Japanese study, a proportion of patients that developed DGC had pangastritis (9/13), moderate to severe atrophy (9/13 and 1/13 respectively) and IM (8/13) at base line[100], suggesting a significant association between IM and DGC development[100]. A more recent study in South Korea showed that OLGA and OLGIM may have clinical utility in patients at risk of developing DGC[101]. Multivariate logistic regression analysis showed family history of GC, *H. pylori*infection, and OLGA/OLGIM stages III/IV were independent risk factors for both IGC and DGC[101]. Thus, atrophy and particularly IM likely play a dual role in GC dependent on the context. If the right conditions are met, cellular and molecular changes within the stem cell compartment of these lesions lead to GCA; if not, their presence creates a permissive environment for progression to GCA to occur, possibly through hypochlorhydria and dysbiosis, and is also an indicator of increased patient progression risk. DGC may be the result of an "alternative" route to carcinogenesis, where a CDH1 mutation within the glandular stem cell compartment of a gastric gland or atrophic gland or even a metaplastic gland/crypt produces a parent tumour cell.

***Neuroendocrine cell dedifferentiation: An alternative route to GC?***

An alternative paradigm to the stem cell theory as the tumour cell of origin has been gaining ground in recent years. In certain circumstances, mature neuroendocrine cells may dedifferentiate, accumulate mutations and other genomic events, and become tumour cells themselves[102]. Neuroendocrine tumours are the most likely results of such an event but also GAs. The enterochromafin-like cell is the main neuroendocrine cell in the oxyntic stomach, which produces and releases histamine and has gastrin receptors. Although the exact molecular and cellular mechanisms of this pathway to GC are not known, it is thought that loss of parietal cells and atrophy precedes cellular dedifferentiation of enterochromafin-like cells. Thus, this pathway to GC may not fully follow the Correa cascade, going directly from an atrophic state to a hyperplastic, then dysplastic and then to either a neuroendocrine tumour or a GA.

## **conclusion**

Our understanding of the molecular basis of GC and its premalignant lesions is accumulating rapidly, providing useful insights into the natural history of the disease (Figure 3). Knowledge remains lacking in many domains; however, including the relationship between premalignant lesions and TCGA subtypes of GC. It could be the molecular changes characterising the TCGA GC subtypes represents disparate insults predisposing to initiation of the Correa cascade. Alternatively, the subtypes could represent accumulated “hits” following initiation of *H. pylori* infection. Insights into this pathway would stratify those at risk as well as inform prognosis and surveillance guidelines. The observation that IM appears to be a relative point of no return along the Correa cascade, with only a small fraction of patients progressing to dysplasia and GC, raises questions of the molecular determinants of progression. In the first study of its type, Huang *et al*[96] laid the foundation for understanding this process, following an IM cohort for a minimum of 5 years and describing the molecular changes associated with progression in a large Chinese cohort. Validation of these findings in alternative cohorts is required for its use clinically. In high-risk populations, screening and surveillance have been successful in the early detection of GCs and improvements in 5-year survival. However further work is required in low-risk populations to make strong evidence-based decisions regarding clinical screening or surveillance. In those known to have IM, the risk factors discussed above should prompt the clinician to carefully consider surveillance including incomplete IM, dysplasia, extensive IM involving the corpus, male gender, and those from high-risk ethnicities. The addition of molecular data such as TP53 mutation data, methylation patterns, and chromosome 8 status would further improve risk-assessment algorithms; however, larger population-based data are required for this to be accurate and practical.

**REFERENCES**

1 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

2 **Joossens JV**, Hill MJ, Elliott P, Stamler R, Lesaffre E, Dyer A, Nichols R, Kesteloot H. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. *Int J Epidemiol* 1996; **25**: 494-504 [PMID: 8671549 DOI: 10.1093/ije/25.3.494]

3 **Haenszel W**, Kurihara M, Segi M, Lee RK. Stomach cancer among Japanese in Hawaii. *J Natl Cancer Inst* 1972; **49**: 969-988 [PMID: 4678140 DOI: 10.1093/jnci/49.4.969]

4 **Strumylaite L**, Zickute J, Dudzevicius J, Dregval L. Salt-preserved foods and risk of gastric cancer. *Medicina (Kaunas)* 2006; **42**: 164-170 [PMID: 16528133]

5 **Lin SH**, Li YH, Leung K, Huang CY, Wang XR. Salt processed food and gastric cancer in a Chinese population. *Asian Pac J Cancer Prev* 2014; **15**: 5293-5298 [PMID: 25040991 DOI: 10.7314/APJCP.2014.15.13.5293]

6 **Ren JS**, Kamangar F, Forman D, Islami F. Pickled food and risk of gastric cancer--a systematic review and meta-analysis of English and Chinese literature. *Cancer Epidemiol Biomarkers Prev* 2012; **21**: 905-915 [PMID: 22499775 DOI: 10.1158/1055-9965.EPI-12-0202]

7 **Tsugane S**, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. *Gastric Cancer* 2007; **10**: 75-83 [PMID: 17577615 DOI: 10.1007/s10120-007-0420-0]

8 **Jenab M**, Riboli E, Ferrari P, Sabate J, Slimani N, Norat T, Friesen M, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Touvier M, Boeing H, Schulz M, Linseisen J, Nagel G, Trichopoulou A, Naska A, Oikonomou E, Krogh V, Panico S, Masala G, Sacerdote C, Tumino R, Peeters PH, Numans ME, Bueno-de-Mesquita HB, Büchner FL, Lund E, Pera G, Sanchez CN, Sánchez MJ, Arriola L, Barricarte A, Quirós JR, Hallmans G, Stenling R, Berglund G, Bingham S, Khaw KT, Key T, Allen N, Carneiro F, Mahlke U, Del Giudice G, Palli D, Kaaks R, Gonzalez CA. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Carcinogenesis* 2006; **27**: 2250-2257 [PMID: 16774936 DOI: 10.1093/carcin/bgl096]

9 **González CA**, Pera G, Agudo A, Palli D, Krogh V, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Agren A, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Bingham S, Day N, Miller A, Nagel G, Boeing H, Overvad K, Tjonneland A, Bueno-De-Mesquita HB, Boshuizen HC, Peeters P, Numans M, Clavel-Chapelon F, Helen I, Agapitos E, Lund E, Fahey M, Saracci R, Kaaks R, Riboli E. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). *Int J Cancer* 2003; **107**: 629-634 [PMID: 14520702 DOI: 10.1002/ijc.11426]

10 **Praud D**, Rota M, Pelucchi C, Bertuccio P, Rosso T, Galeone C, Zhang ZF, Matsuo K, Ito H, Hu J, Johnson KC, Yu GP, Palli D, Ferraroni M, Muscat J, Lunet N, Peleteiro B, Malekzadeh R, Ye W, Song H, Zaridze D, Maximovitch D, Aragonés N, Castaño-Vinyals G, Vioque J, Navarrete-Muñoz EM, Pakseresht M, Pourfarzi F, Wolk A, Orsini N, Bellavia A, Håkansson N, Mu L, Pastorino R, Kurtz RC, Derakhshan MH, Lagiou A, Lagiou P, Boffetta P, Boccia S, Negri E, La Vecchia C. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) Project. *Eur J Cancer Prev* 2018; **27**: 124-133 [PMID: 27560662 DOI: 10.1097/CEJ.0000000000000290]

11 **Han MA**, Kim YW, Choi IJ, Oh MG, Kim CG, Lee JY, Cho SJ, Eom BW, Yoon HM, Ryu KW. Association of smoking history with cancer recurrence and survival in stage III-IV male gastric cancer patients. *Cancer Epidemiol Biomarkers Prev* 2013; **22**: 1805-1812 [PMID: 23904463 DOI: 10.1158/1055-9965.EPI-13-0385]

12 **Preston DL**, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. Solid cancer incidence in atomic bomb survivors: 1958-1998. *Radiat Res* 2007; **168**: 1-64 [PMID: 17722996 DOI: 10.1667/RR0763.1]

13 **Abioye AI**, Odesanya MO, Abioye AI, Ibrahim NA. Physical activity and risk of gastric cancer: a meta-analysis of observational studies. *Br J Sports Med* 2015; **49**: 224-229 [PMID: 24434186 DOI: 10.1136/bjsports-2013-092778]

14 **O'Doherty MG**, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. *Gut* 2012; **61**: 1261-1268 [PMID: 22174193 DOI: 10.1136/gutjnl-2011-300551]

15 **Uthman OA**, Jadidi E, Moradi T. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. *J Epidemiol Community Health* 2013; **67**: 854-860 [PMID: 23929615 DOI: 10.1136/jech-2012-201108]

16 **Lauren P**. The Two Histological Main Types Of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at A Histo-Clinical Classification. *Acta Pathol Microbiol Scand* 1965; **64**: 31-49 [PMID: 14320675 DOI: 10.1111/apm.1965.64.1.31]

17 **Cancer Genome Atlas Research Network.** Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]

18 **Correa P**, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. *Lancet* 1975; **2**: 58-60 [PMID: 49653 DOI: 10.1016/S0140-6736(75)90498-5]

19 **Kim N**, Park RY, Cho SI, Lim SH, Lee KH, Lee W, Kang HM, Lee HS, Jung HC, Song IS. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. *J Clin Gastroenterol* 2008; **42**: 448-454 [PMID: 18344895 DOI: 10.1097/MCG.0b013e318046eac3]

20 **Blaser MJ**, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Res* 1995; **55**: 2111-2115 [PMID: 7743510 DOI: 10.1002/1097-0142(19950515)75:10<2623::AID-CNCR2820751033>3.0.CO]

21 **Wroblewski LE**, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. *Clin Microbiol Rev* 2010; **23**: 713-739 [PMID: 20930071 DOI: 10.1128/CMR.00011-10]

22 **Murata-Kamiya N**. Pathophysiological functions of the CagA oncoprotein during infection by Helicobacter pylori. *Microbes Infect* 2011; **13**: 799-807 [PMID: 21477660 DOI: 10.1016/j.micinf.2011.03.011]

23 **Hatakeyama M**. Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer. *Proc Jpn Acad Ser B Phys Biol Sci* 2017; **93**: 196-219 [PMID: 28413197 DOI: 10.2183/pjab.93.013]

24 **Na HK**, Woo JH. Helicobacter pylori Induces Hypermethylation of CpG Islands Through Upregulation of DNA Methyltransferase: Possible Involvement of Reactive Oxygen/Nitrogen Species. *J Cancer Prev* 2014; **19**: 259-264 [PMID: 25574460 DOI: 10.15430/JCP.2014.19.4.259]

25 **Schneider BG**, Piazuelo MB, Sicinschi LA, Mera R, Peng DF, Roa JC, Romero-Gallo J, Delgado AG, de Sablet T, Bravo LE, Wilson KT, El-Rifai W, Peek RM Jr, Correa P. Virulence of infecting Helicobacter pylori strains and intensity of mononuclear cell infiltration are associated with levels of DNA hypermethylation in gastric mucosae. *Epigenetics* 2013; **8**: 1153-1161 [PMID: 24128875 DOI: 10.4161/epi.26072]

26 **Coati I**, Fassan M, Farinati F, Graham DY, Genta RM, Rugge M. Autoimmune gastritis: Pathologist's viewpoint. *World J Gastroenterol* 2015; **21**: 12179-12189 [PMID: 26576102 DOI: 10.3748/wjg.v21.i42.12179]

27 **Vannella L**, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. *Aliment Pharmacol Ther* 2013; **37**: 375-382 [PMID: 23216458 DOI: 10.1111/apt.12177]

28 **Parsons BN**, Ijaz UZ, D'Amore R, Burkitt MD, Eccles R, Lenzi L, Duckworth CA, Moore AR, Tiszlavicz L, Varro A, Hall N, Pritchard DM. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. *PLoS Pathog* 2017; **13**: e1006653 [PMID: 29095917 DOI: 10.1371/journal.ppat.1006653]

29 **Coker OO**, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY, Yu J. Mucosal microbiome dysbiosis in gastric carcinogenesis. *Gut* 2018; **67**: 1024-1032 [PMID: 28765474 DOI: 10.1136/gutjnl-2017-314281]

30 **Kawanishi S**, Hiraku Y, Oikawa S. Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging. *Mutat Res* 2001; **488**: 65-76 [PMID: 11223405 DOI: 10.1016/S1383-5742(00)00059-4]

31 **Hussain SP**, Harris CC. Inflammation and cancer: an ancient link with novel potentials. *Int J Cancer* 2007; **121**: 2373-2380 [PMID: 17893866 DOI: 10.1002/ijc.23173]

32 **Jaiswal M**, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. *Am J Physiol Gastrointest Liver Physiol* 2001; **281**: G626-G634 [PMID: 11518674 DOI: 10.1152/ajpgi.2001.281.3.G626]

33 **Barker N**, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, Stange DE, Begthel H, van den Born M, Danenberg E, van den Brink S, Korving J, Abo A, Peters PJ, Wright N, Poulsom R, Clevers H. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. *Cell Stem Cell* 2010; **6**: 25-36 [PMID: 20085740 DOI: 10.1016/j.stem.2009.11.013]

34 **Waddingham W**, Graham D, Banks M, Jansen M. The evolving role of endoscopy in the diagnosis of premalignant gastric lesions. *F1000Res* 2018; **7**: [PMID: 29946429 DOI: 10.12688/f1000research.12087.1]

35 **Hayakawa Y**, Ariyama H, Stancikova J, Sakitani K, Asfaha S, Renz BW, Dubeykovskaya ZA, Shibata W, Wang H, Westphalen CB, Chen X, Takemoto Y, Kim W, Khurana SS, Tailor Y, Nagar K, Tomita H, Hara A, Sepulveda AR, Setlik W, Gershon MD, Saha S, Ding L, Shen Z, Fox JG, Friedman RA, Konieczny SF, Worthley DL, Korinek V, Wang TC. Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche. *Cancer Cell* 2015; **28**: 800-814 [PMID: 26585400 DOI: 10.1016/j.ccell.2015.10.003]

36 **Stange DE**, Koo BK, Huch M, Sibbel G, Basak O, Lyubimova A, Kujala P, Bartfeld S, Koster J, Geahlen JH, Peters PJ, van Es JH, van de Wetering M, Mills JC, Clevers H. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. *Cell* 2013; **155**: 357-368 [PMID: 24120136 DOI: 10.1016/j.cell.2013.09.008]

37 **Jass JR**, Filipe MI. A variant of intestinal metaplasia associated with gastric carcinoma: a histochemical study. *Histopathology* 1979; **3**: 191-199 [PMID: 468122 DOI: 10.1111/j.1365-2559.1979.tb02996.x]

38 **Reis CA**, David L, Correa P, Carneiro F, de Bolós C, Garcia E, Mandel U, Clausen H, Sobrinho-Simões M. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. *Cancer Res* 1999; **59**: 1003-1007 [PMID: 10070955]

39 **González CA**, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. *Int J Cancer* 2013; **133**: 1023-1032 [PMID: 23280711 DOI: 10.1002/ijc.28003]

40 **González CA**, Sanz-Anquela JM, Companioni O, Bonet C, Berdasco M, López C, Mendoza J, Martín-Arranz MD, Rey E, Poves E, Espinosa L, Barrio J, Torres MÁ, Cuatrecasas M, Elizalde I, Bujanda L, Garmendia M, Ferrández Á, Muñoz G, Andreu V, Paules MJ, Lario S, Ramírez MJ; Study group, Gisbert JP. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. *J Gastroenterol Hepatol* 2016; **31**: 953-958 [PMID: 26630310 DOI: 10.1111/jgh.13249]

41 **Pittayanon R**, Rerknimitr R, Klaikaew N, Sanpavat A, Chaithongrat S, Mahachai V, Kullavanijaya P, Barkun A. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. *Aliment Pharmacol Ther* 2017; **46**: 40-45 [PMID: 28449219 DOI: 10.1111/apt.14082]

42 **Shao L**, Li P, Ye J, Chen J, Han Y, Cai J, Lu X. Risk of gastric cancer among patients with gastric intestinal metaplasia. *Int J Cancer* 2018 [PMID: 29707766 DOI: 10.1002/ijc.31571]

43 **Giroux V**, Rustgi AK. Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence. *Nat Rev Cancer* 2017; **17**: 594-604 [PMID: 28860646 DOI: 10.1038/nrc.2017.68]

44 **Mutoh H**, Sakurai S, Satoh K, Tamada K, Kita H, Osawa H, Tomiyama T, Sato Y, Yamamoto H, Isoda N, Yoshida T, Ido K, Sugano K. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. *Cancer Res* 2004; **64**: 7740-7747 [PMID: 15520178 DOI: 10.1158/0008-5472.CAN-04-1617]

45 **Camilo V**, Barros R, Sousa S, Magalhães AM, Lopes T, Mário Santos A, Pereira T, Figueiredo C, David L, Almeida R. Helicobacter pylori and the BMP pathway regulate CDX2 and SOX2 expression in gastric cells. *Carcinogenesis* 2012; **33**: 1985-1992 [PMID: 22791809 DOI: 10.1093/carcin/bgs233]

46 **Camilo V**, Garrido M, Valente P, Ricardo S, Amaral AL, Barros R, Chaves P, Carneiro F, David L, Almeida R. Differentiation reprogramming in gastric intestinal metaplasia and dysplasia: role of SOX2 and CDX2. *Histopathology* 2015; **66**: 343-350 [PMID: 25196071 DOI: 10.1111/his.12544]

47 **Asano N**, Imatani A, Watanabe T, Fushiya J, Kondo Y, Jin X, Ara N, Uno K, Iijima K, Koike T, Strober W, Shimosegawa T. Cdx2 Expression and Intestinal Metaplasia Induced by H. pylori Infection of Gastric Cells Is Regulated by NOD1-Mediated Innate Immune Responses. *Cancer Res* 2016; **76**: 1135-1145 [PMID: 26759244 DOI: 10.1158/0008-5472.CAN-15-2272]

48 **Sobala GM**, O'Connor HJ, Dewar EP, King RF, Axon AT, Dixon MF. Bile reflux and intestinal metaplasia in gastric mucosa. *J Clin Pathol* 1993; **46**: 235-240 [PMID: 8463417 DOI: 10.1136/jcp.46.3.235]

49 **Matsuhisa T**, Arakawa T, Watanabe T, Tokutomi T, Sakurai K, Okamura S, Chono S, Kamada T, Sugiyama A, Fujimura Y, Matsuzawa K, Ito M, Yasuda M, Ota H, Haruma K. Relation between bile acid reflux into the stomach and the risk of atrophic gastritis and intestinal metaplasia: a multicenter study of 2283 cases. *Dig Endosc* 2013; **25**: 519-525 [PMID: 23363381 DOI: 10.1111/den.12030]

50 **Genta RM**, Sonnenberg A. Characteristics of the gastric mucosa in patients with intestinal metaplasia. *Am J Surg Pathol* 2015; **39**: 700-704 [PMID: 25602799 DOI: 10.1097/PAS.0000000000000384]

51 **Lissowska J**, Groves FD, Sobin LH, Fraumeni JF Jr, Nasierowska-Guttmejer A, Radziszewski J, Regula J, Hsing AW, Zatonski W, Blot WJ, Chow WH. Family history and risk of stomach cancer in Warsaw, Poland. *Eur J Cancer Prev* 1999; **8**: 223-227 [PMID: 10443951 DOI: 10.1097/00008469-199906000-00010]

52 **Eto K**, Ohyama S, Yamaguchi T, Wada T, Suzuki Y, Mitsumori N, Kashiwagi H, Anazawa S, Yanaga K, Urashima M. Familial clustering in subgroups of gastric cancer stratified by histology, age group and location. *Eur J Surg Oncol* 2006; **32**: 743-748 [PMID: 16762526 DOI: 10.1016/j.ejso.2006.04.005]

53 **Shin CM**, Kim N, Lee HS, Lee DH, Kim JS, Jung HC, Song IS. Intrafamilial aggregation of gastric cancer: a comprehensive approach including environmental factors, Helicobacter pylori virulence, and genetic susceptibility. *Eur J Gastroenterol Hepatol* 2011; **23**: 411-417 [PMID: 21502924 DOI: 10.1097/MEG.0b013e328343b7f5]

54 **Song H**, Ekheden IG, Ploner A, Ericsson J, Nyren O, Ye W. Family history of gastric mucosal abnormality and the risk of gastric cancer: a population-based observational study. *Int J Epidemiol* 2018; **47**: 440-449 [PMID: 29161426 DOI: 10.1093/ije/dyx238]

55 **Cassaro M**, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. *Am J Gastroenterol* 2000; **95**: 1431-1438 [PMID: 10894575 DOI: 10.1111/j.1572-0241.2000.02074.x]

56 **Sakitani K**, Hirata Y, Watabe H, Yamada A, Sugimoto T, Yamaji Y, Yoshida H, Maeda S, Omata M, Koike K. Gastric cancer risk according to the distribution of intestinal metaplasia and neutrophil infiltration. *J Gastroenterol Hepatol* 2011; **26**: 1570-1575 [PMID: 21575058 DOI: 10.1111/j.1440-1746.2011.06767.x]

57 **Hamamoto T**, Yokozaki H, Semba S, Yasui W, Yunotani S, Miyazaki K, Tahara E. Altered microsatellites in incomplete-type intestinal metaplasia adjacent to primary gastric cancers. *J Clin Pathol* 1997; **50**: 841-846 [PMID: 9462267 DOI: 10.1136/jcp.50.10.841]

58 **Dixon MF**, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; **20**: 1161-1181 [PMID: 8827022 DOI: 10.1097/00000478-199610000-00001]

59 **Rugge M**, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, Genta RM, Graham DY, Hattori T, Malfertheiner P, Nakajima S, Sipponen P, Sung J, Weinstein W, Vieth M. OLGA staging for gastritis: a tutorial. *Dig Liver Dis* 2008; **40**: 650-658 [PMID: 18424244 DOI: 10.1016/j.dld.2008.02.030]

60 **Capelle LG**, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. *Gastrointest Endosc* 2010; **71**: 1150-1158 [PMID: 20381801 DOI: 10.1016/j.gie.2009.12.029]

61 **Rugge M**, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, Basso D, Plebani M, Graham DY. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. *Aliment Pharmacol Ther* 2010; **31**: 1104-1111 [PMID: 20180784 DOI: 10.1111/j.1365-2036.2010.04277.x]

62 **Rugge M**, Fassan M, Pizzi M, Farinati F, Sturniolo GC, Plebani M, Graham DY. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. *World J Gastroenterol* 2011; **17**: 4596-4601 [PMID: 22147965 DOI: 10.3748/wjg.v17.i41.4596]

63 **Yue H**, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. *Gastric Cancer* 2018; **21**: 579-587 [PMID: 29460004 DOI: 10.1007/s10120-018-0812-3]

64 **Rokkas T**, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. *Helicobacter* 2007; **12** Suppl 2: 32-38 [PMID: 17991174 DOI: 10.1111/j.1523-5378.2007.00563.x]

65 **Wang J**, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. *Digestion* 2011; **83**: 253-260 [PMID: 21282951 DOI: 10.1159/000280318]

66 **Shin CM**, Kim N, Chang H, Kim JS, Lee DH, Jung HC. Follow-Up Study on CDX1 and CDX2 mRNA Expression in Noncancerous Gastric Mucosae After Helicobacter pylori Eradication. *Dig Dis Sci* 2016; **61**: 1051-1059 [PMID: 26841784 DOI: 10.1007/s10620-016-4048-y]

67 **Chen HN**, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. *Gastric Cancer* 2016; **19**: 166-175 [PMID: 25609452 DOI: 10.1007/s10120-015-0462-7]

68 **den Hollander WJ**, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten MP, Prytz-Berset I, Witteman EM, Ter Borg F, Hartog GD, Bruno MJ, Peppelenbosch MP, Lesterhuis W, Doukas M, Kuipers EJ, Spaander MCW. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. *Gut* 2019; **68**: 585-593 [PMID: 29875257 DOI: 10.1136/gutjnl-2017-314498]

69 **Sung JJ**, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. *Gastroenterology* 2000; **119**: 7-14 [PMID: 10889149 DOI: 10.1053/gast.2000.8550]

70 **Arkkila PE**, Seppälä K, Färkkilä MA, Veijola L, Sipponen P. Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study. *Scand J Gastroenterol* 2006; **41**: 782-790 [PMID: 16785190 DOI: 10.1080/00365520500463175]

71 **Toyokawa T**, Suwaki K, Miyake Y, Nakatsu M, Ando M. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. *J Gastroenterol Hepatol* 2010; **25**: 544-547 [PMID: 19817964 DOI: 10.1111/j.1440-1746.2009.05995.x]

72 **González CA**, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. *Int J Cancer* 2010; **127**: 2654-2660 [PMID: 20178099 DOI: 10.1002/ijc.25273]

73 **Reddy KM**, Chang JI, Shi JM, Wu BU. Risk of Gastric Cancer Among Patients With Intestinal Metaplasia of the Stomach in a US Integrated Health Care System. *Clin Gastroenterol Hepatol* 2016; **14**: 1420-1425 [PMID: 27317852 DOI: 10.1016/j.cgh.2016.05.045]

74 **Schmidt PH**, Lee JR, Joshi V, Playford RJ, Poulsom R, Wright NA, Goldenring JR. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. *Lab Invest* 1999; **79**: 639-646 [PMID: 10378506 DOI: 10.1121/1.424682]

75 **Wang TC**, Goldenring JR, Dangler C, Ito S, Mueller A, Jeon WK, Koh TJ, Fox JG. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. *Gastroenterology* 1998; **114**: 675-689 [PMID: 9516388 DOI: 10.1016/S0016-5085(98)70581-5]

76 **Halldórsdóttir AM**, Sigurdardóttrir M, Jónasson JG, Oddsdóttir M, Magnússon J, Lee JR, Goldenring JR. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. *Dig Dis Sci* 2003; **48**: 431-441 [PMID: 12757153 DOI: 10.1023/A:1022564027468]

77 **Nam KT**, Lee HJ, Sousa JF, Weis VG, O'Neal RL, Finke PE, Romero-Gallo J, Shi G, Mills JC, Peek RM Jr, Konieczny SF, Goldenring JR. Mature chief cells are cryptic progenitors for metaplasia in the stomach. *Gastroenterology* 2010; **139**: 2028-2037.e9 [PMID: 20854822 DOI: 10.1053/j.gastro.2010.09.005]

78 **Weis VG**, Petersen CP, Weis JA, Meyer AR, Choi E, Mills JC, Goldenring JR. Maturity and age influence chief cell ability to transdifferentiate into metaplasia. *Am J Physiol Gastrointest Liver Physiol* 2017; **312**: G67-G76 [PMID: 27881402 DOI: 10.1152/ajpgi.00326.2016]

79 **Kinoshita H**, Hayakawa Y, Niu Z, Konishi M, Hata M, Tsuboi M, Hayata Y, Hikiba Y, Ihara S, Nakagawa H, Hirata Y, Wang TC, Koike K. Mature gastric chief cells are not required for the development of metaplasia. *Am J Physiol Gastrointest Liver Physiol* 2018; **314**: G583-G596 [PMID: 29345968 DOI: 10.1152/ajpgi.00351.2017]

80 **Wang TC**, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. *Gastroenterology* 2000; **118**: 36-47 [PMID: 10611152 DOI: 10.1016/S0016-5085(00)70412-4]

81 **Shimizu T**, Choi E, Petersen CP, Noto JM, Romero-Gallo J, Piazuelo MB, Washington MK, Peek RM Jr, Goldenring JR. Characterization of progressive metaplasia in the gastric corpus mucosa of Mongolian gerbils infected with Helicobacter pylori. *J Pathol* 2016; **239**: 399-410 [PMID: 27125972 DOI: 10.1002/path.4735]

82 **Goldenring JR**, Nam KT, Wang TC, Mills JC, Wright NA. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. *Gastroenterology* 2010; **138**: 2207-2210, 2210.e1 [PMID: 20450866 DOI: 10.1053/j.gastro.2010.04.023]

83 **Petersen CP**, Weis VG, Nam KT, Sousa JF, Fingleton B, Goldenring JR. Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells. *Gastroenterology* 2014; **146**: 1727-38.e8 [PMID: 24534633 DOI: 10.1053/j.gastro.2014.02.007]

84 **Fu H**, Ma Y, Yang M, Zhang C, Huang H, Xia Y, Lu L, Jin W, Cui D. Persisting and Increasing Neutrophil Infiltration Associates with Gastric Carcinogenesis and E-cadherin Downregulation. *Sci Rep* 2016; **6**: 29762 [PMID: 27412620 DOI: 10.1038/srep29762]

85 **McDonald SA**, Greaves LC, Gutierrez-Gonzalez L, Rodriguez-Justo M, Deheragoda M, Leedham SJ, Taylor RW, Lee CY, Preston SL, Lovell M, Hunt T, Elia G, Oukrif D, Harrison R, Novelli MR, Mitchell I, Stoker DL, Turnbull DM, Jankowski JA, Wright NA. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. *Gastroenterology* 2008; **134**: 500-510 [PMID: 18242216 DOI: 10.1053/j.gastro.2007.11.035]

86 **Gutierrez-Gonzalez L**, Graham TA, Rodriguez-Justo M, Leedham SJ, Novelli MR, Gay LJ, Ventayol-Garcia T, Green A, Mitchell I, Stoker DL, Preston SL, Bamba S, Yamada E, Kishi Y, Harrison R, Jankowski JA, Wright NA, McDonald SA. The clonal origins of dysplasia from intestinal metaplasia in the human stomach. *Gastroenterology* 2011; **140**: 1251-1260.e1-6 [PMID: 21223968 DOI: 10.1053/j.gastro.2010.12.051]

87 **Jung SH**, Kim SY, An CH, Lee SH, Jung ES, Park HC, Kim MS, Chung YJ, Lee SH. Clonal Structures of Regionally Synchronous Gastric Adenomas and Carcinomas. *Clin Cancer Res* 2018; **24**: 4715-4725 [PMID: 29945994 DOI: 10.1158/1078-0432.CCR-18-0345]

88 **Schoofs N**, Bisschops R, Prenen H. Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview. *Ann Gastroenterol* 2017; **30**: 1-6 [PMID: 28042232 DOI: 10.20524/aog.2016.0091]

89 **de Jonge PJ**, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. *Gut* 2010; **59**: 1030-1036 [PMID: 20639249 DOI: 10.1136/gut.2009.176701]

90 **Hvid-Jensen F**, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011; **365**: 1375-1383 [PMID: 21995385 DOI: 10.1056/NEJMoa1103042]

91 **Ross-Innes CS**, Becq J, Warren A, Cheetham RK, Northen H, O'Donovan M, Malhotra S, di Pietro M, Ivakhno S, He M, Weaver JMJ, Lynch AG, Kingsbury Z, Ross M, Humphray S, Bentley D, Fitzgerald RC. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. *Nat Genet* 2015; **47**: 1038-1046 [PMID: 26192915 DOI: 10.1038/ng.3357]

92 **Campbell JD**, Mazzilli SA, Reid ME, Dhillon SS, Platero S, Beane J, Spira AE. The Case for a Pre-Cancer Genome Atlas (PCGA). *Cancer Prev Res (Phila)* 2016; **9**: 119-124 [PMID: 26839336 DOI: 10.1158/1940-6207.CAPR-16-0024]

93 **Kim HJ**, Kang TW, Haam K, Kim M, Kim SK, Kim SY, Lee SI, Song KS, Jeong HY, Kim YS. Whole genome MBD-seq and RRBS analyses reveal that hypermethylation of gastrointestinal hormone receptors is associated with gastric carcinogenesis. *Exp Mol Med* 2018; **50**: 156 [PMID: 30510283 DOI: 10.1038/s12276-018-0179-x]

94 **Rivas-Ortiz CI**, Lopez-Vidal Y, Arredondo-Hernandez LJR, Castillo-Rojas G. Genetic Alterations in Gastric Cancer Associated with <i>Helicobacter pylori</i> Infection. *Front Med (Lausanne)* 2017; **4**: 47 [PMID: 28512631 DOI: 10.3389/fmed.2017.00047]

95 **Li D**, Bautista MC, Jiang SF, Daryani P, Brackett M, Armstrong MA, Hung YY, Postlethwaite D, Ladabaum U. Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study. *Am J Gastroenterol* 2016; **111**: 1104-1113 [PMID: 27185078 DOI: 10.1038/ajg.2016.188]

96 **Huang KK**, Ramnarayanan K, Zhu F, Srivastava S, Xu C, Tan ALK, Lee M, Tay S, Das K, Xing M, Fatehullah A, Alkaff SMF, Lim TKH, Lee J, Ho KY, Rozen SG, Teh BT, Barker N, Chia CK, Khor C, Ooi CJ, Fock KM, So J, Lim WC, Ling KL, Ang TL, Wong A, Rao J, Rajnakova A, Lim LG, Yap WM, Teh M, Yeoh KG, Tan P. Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. *Cancer Cell* 2018; **33**: 137-150.e5 [PMID: 29290541 DOI: 10.1016/j.ccell.2017.11.018]

97 **Busuttil RA**, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N, Fox S, Haupt Y, Dobrovic A, Boussioutas A. Role of p53 in the progression of gastric cancer. *Oncotarget* 2014; **5**: 12016-12026 [PMID: 25427447 DOI: 10.18632/oncotarget.2434]

98 **Rugge M**, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, Riddell RH, Sipponen P, Watanabe H. Gastric dysplasia: the Padova international classification. *Am J Surg Pathol* 2000; **24**: 167-176 [PMID: 10680883 DOI: 10.1097/00000478-200002000-00001]

99 **Rokutan H**, Abe H, Nakamura H, Ushiku T, Arakawa E, Hosoda F, Yachida S, Tsuji Y, Fujishiro M, Koike K, Totoki Y, Fukayama M, Shibata T. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia. *J Pathol* 2019; **247**: 494-504 [PMID: 30474112 DOI: 10.1002/path.5208]

100 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297 DOI: 10.1056/NEJMoa001999]

101 **Yun CY**, Kim N, Lee J, Lee JY, Hwang YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JW, Lee DH. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors. *Helicobacter* 2018; **23**: e12542 [PMID: 30303591 DOI: 10.1111/hel.12542]

102 **Waldum HL**, Öberg K, Sørdal ØF, Sandvik AK, Gustafsson BI, Mjønes P, Fossmark R. Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift. *Therap Adv Gastroenterol* 2018; **11**: 1756284818775054 [PMID: 29872453 DOI: 10.1177/1756284818775054]

**P-Reviewer:** De Silva AP, Gassler N, Park WS **S-Editor:** Ma YJ

**L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Oncology

**Country of origin:** Australia

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**A**



**B**



**C**



**D**



**E**

\*

\*

\*

\*

**Figure 1 complete or incomplete subtypes.** A: CG with mucosal atrophy and lymphocytic infiltrate (asterix); B: Incomplete IM resembling the colonic-type epithelium with irregular mucin droplets (arrowheads) and absence of a brush border; C: Complete IM resembling the small intestinal epithelium with goblet cells alternating with eosinophilic enterocytes, brush border, and Paneth cells; D: LGC characterised by crowded glands with columnar cells and preserved polarity and pseudostratified nuclei; E: HGD with cuboidal cells, mitotic activity, prominent nucleoli, and high nuclear-cytoplasmic ratio.

**Normal**

**mucosa**

**Intestinal**

**metaplasia**

**Dysplasia**

**Gastric**

**cancer**

**Atrophic**

**gastritis**

**Chronic**

**gastritis**

**Sung *et al*[69], 2000**

*n* = 587, mean 1 yr follow up

Control

**Arkkila *et al*[70], 2006**

*n* = 92, median 1 yr follow up

**Toyokawa *et al*[71], 2010**

*n* = 241, mean 8.4 yr follow up

*H. pylori* Rx

**Gonzalez *et al*[40], 2016**

*n* = 649, mean 12 yr follow up

**Gonzalez *et al*[72], 2010**

*n* = 478, mean 12.8 yr follow up

CIM

CIM

IIM

IIM

**Reddy *et al*[73], 2016**

*n* = 923, median 4.6 yr follow up

*H. pylori* Rx

**Den Hollander *et al*[68], 2018**

*n* = 279, mean 4.8 yr follow up

LGD

HGD

*H. pylori* Rx

**Figure 2 Graphical representation of selected large studies investigating progression/regression of premalignant gastric lesions across the stages of the Correa cascade.** Arrows represent the direction of effect findings, with the size of the arrow the strength of effect (not to scale between cohorts and only major findings of trials represented). H. pylori Rx: Helicobacter pylori antibiotic therapy; CIM: complete IM; IIM: incomplete IM; LGD: low-grade dysplasia; HGD: high-grade dysplasia; IM: Intestinal metaplasia.

Corpus

pit

isthmus

neck

base

pit

isthmus

neck

base

Antrum

1st step to oncogenesis

(reversible)

2nd step to oncogenesis

(mainly reversible)

**Chronic gastritis**

**Atrophic gastritis**

Cell and molecular events:

DNA methylation, p53/ RUNX3 degradation, PI3K-AKT/Ras-ERK/Wnt pathways deregu-lated, adherens junctions disrupted, reactive oxygen species, increased DNA damage

Parietal cell loss

Hypochloridia

Microbiome changes

Chr. 8 amplification

Telomeres shortened

FBXW7 mutation

DNA hypermethylation

Risk factors:

Incomplete IM

IM in corpus

IM in Maggenstrasse

Severe IM

OLGIM III/IV

Severe atrophy

OLGA III/IV

Pepsinogen levels

3rd step to oncogenesis

(partially reversible)

**Intestinal metaplasia**

Complete

Incomplete

LGR5

LGR5

4th step to oncogenesis

(mainly irreversible)

**Dysplasia**

**Gastric cancer**

Diffuse

GS

Intestinal

CIN

MSI

EBV

High-grade

Low-grade

TP53

mutation

APC

mutation

+ *H. pylori*

CagA strain

CDH1

mutation

Mist1

+ *H. pylori*

LGR5

LGR5

APC

mutation

TP53

mutation

??

??

??

??

**Figure 3 Summary of the cellular and molecular events associated with progression to cancer.** H. pylori: Helicobacter pylori; EBV: Epstein Barr virus-positive; MSI: microsatellite instability; CagA: cytotoxin-associated gene A protein; IM: Intestinal metaplasia; GS: genomically stable.